AGM
DFTX

Alpine Global Management’s Definium Therapeutics DFTX Stock Holding History

Alpine Global Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-68,176
Closed -$492K – 331
2024
Q2 		$492K Buy
+68,176
New +$596K 0.09% 181
2022
Q3 		– Sell
-2,117
Closed -$20K – 484
2022
Q2 		$20K Hold
2,117
– – 0.01% 198
2022
Q1 		$35 Sell
2,117
-1,862
-47% -$32.3K 0.01% 327
2021
Q4 		$82K Buy
+3,979
New +$127K 0.01% 696

Other funds holding DFTX

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alpine Global Management's DFTX Position: Q3 2024 in Review

Alpine Global Management sold out of Definium Therapeutics (DFTX) in Q3 2024, closing a stake of 68,176 shares — an estimated $492K sold.

Alpine Global Management first reported a position in DFTX in Q4 2021 and held it in 4 quarters. The position peaked at $492K in Q2 2024. 157 funds tracked by Wall St. Rank hold DFTX as of Q3 2024.

  • Alpine Global Management reported no remaining Definium Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 68,176 Definium Therapeutics shares in Q3 2024, an estimated $492K.
  • Alpine Global Management first reported a position in Definium Therapeutics in Q4 2021 and held it in 4 quarters.
  • Alpine Global Management's Definium Therapeutics position peaked at $492K in Q2 2024.
  • 157 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.